NCT05816785View on ClinicalTrials.gov

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Head and Neck CancerSquamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Cetuximab

Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2

DRUG

Imatinib

400 mg orally daily

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER